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Abstract




excellent sensitivity to detect carcinoid tumour lesions.
18F-dopa tumour uptake and the levels of biochemical
tumour markers are mediated by tumour endocrine meta-
bolic activity. We evaluated whether total
18F-dopa tumour
uptake on PET, defined as whole-body metabolic tumour
burden (WBMTB), reflects tumour load per patient, as
measured with tumour markers.
Methods Seventy-seven consecutive carcinoid patients who
underwent an
18F-dopa PET scan in two previously
published studies were analysed. For all tumour lesions
mean standardised uptake values (SUVs) at 40% of the
maximal SUVand tumour volume on
18F-dopa PET were
determined and multiplied to calculate a metabolic burden
per lesion. WBMTB was the sum of the metabolic burden
of all individual lesions per patient. The 24-h urinary
serotonin, urine and plasma 5-hydroxindoleacetic acid (5-
HIAA), catecholamines (nor)epinephrine, dopamine and
their metabolites, measured in urine and plasma, and serum
chromogranin A served as tumour markers.
Results All but 1 were evaluable for WBMTB; 74 patients
had metastatic disease.
18F-dopa PET detected 979 lesions.
SUVmax on
18F-dopa PET varied up to 29-fold between
individual lesions within the same patients. WBMTB
correlated with urinary serotonin (r=0.51) and urinary and
plasma 5-HIAA (r=0.78 and 0.66). WBMTB also corre-
lated with urinary norepinephrine, epinephrine, dopamine
and plasma dopamine, but not with serum chromogranin A.
Conclusion Tumour load per patient measured with
18F-
dopa PET correlates with tumour markers of the serotonin
and catecholamine pathway in urine and plasma in





Carcinoids are rare tumours arising from neuroendocrine
cells, which can produce and secrete a variety of
biochemical markers, including serotonin. Carcinoid
tumours can produce several other markers including
catecholamines in 48% of patients [1–3]. Measuring
urinary 5-hydroxindoleacetic acid (5-HIAA), the main
metabolite of serotonin, is currently the cornerstone in the
diagnosis and response evaluation of metastatic carcinoid
tumours, in combination with data provided by computed
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[4]. Recently, it has been suggested that serum chromog-
ranin A is a better marker than urinary 5-HIAA excretion
for follow-up of carcinoid patients [5, 6]. The disadvan-
tage of urinary 5-HIAA is that the collection of 24-h urine
samples can be unreliable and is inconvenient for the
patient [7]. Therefore a more convenient and accurate
marker is of interest. But in contrast to 5-HIAA, serum
chromogranin A does not reflect the metabolic status of
these tumours [6, 8].
The intrinsic property of neuroendocrine tumour cells to
take up and decarboxylate amine precursors, which is
reflected in the secretory activity of these tumours, is also
used for positron emission tomography (PET) imaging of




excellent sensitivity to detect carcinoid tumour lesions
[9–11]. In the intracellular accumulation of
18F-dopa by
neuroendocrine tumours several essential steps play a role.
18F-dopa is transported into the cell by the L-type amino
acid transporter (LA T), which transports large neutral amino
acids, and then decarboxylated by aromatic L-amino acid
decarboxylase (AADC), resulting in the formation of
18F-
dopamine. This is subsequently transported into specific
storage vesicles by vesicular monoamine transporter and
protected from enzymatic degradation. Unstored
18F-dopa-
mine is subject to degradation in the cytosol and the
metabolites formed leave the cell via diffusion [12]. The
increased demand for precursors by the overactive secretory
pathways in carcinoid tumours induces high
18F-dopa
uptake in tumour cells [2, 13].
Currently, functional information of PET is increasingly
being incorporated into staging and follow-up. This
information complements the anatomical information, such
as exact size and location of lesions, provided by CT and
MRI [14–17]. Whether
18F-dopa PETcan also complement
biochemical tumour markers or become a surrogate marker
is as yet unknown.
Attempts to quantitate metabolic disease activity are
usually based on the maximum standardised uptake value
(SUVmax) and the mean standardised uptake value
(SUVmean) within a certain volume of interest (VOI). PET
imaging additionally opens ways to analyse whole-body
metabolic tumour burden (WBMTB) as a quantitative
measure of the overall tumour load. This approach was
used with
18F-fluorodeoxyglucose (FDG) PET in non-
Hodgkin’s lymphoma to measure the treatment response
after chemotherapy with glucose uptake in the tumour. With
PET WBMTB was the best measure of overall response
when compared with SUVmax and SUVmean [18].
With the increasing use of
18F-dopa PET it is desirable to
know whether the metabolic endocrine tumour activity
measured by biochemical markers in plasma and urine
correlates with metabolic activity, as measured on
18F-dopa
PET. Therefore, the aim of the present study was to evaluate
Table 1 Patient characteristics
Number of evaluable patients 76
Sex (n: male/female) 42/34
Age median (range) 58 (17–79)
New patients vs patients with known disease (n) 30/46
Metastatic disease (n)7 4
Location of primary tumour
Bronchus (n)5
Duodenum (n)4
Small intestine: jejunum-ileum (n)6 2
Colon (n)5
Treatment
Somatostatin analogue treatment (n)2 8
Interferon treatment (n)2
Fig. 1 Example of an
18F-dopa PET scan of a patient with a
semiautomatically generated VOI of a carcinoid lesion
Eur J Nucl Med Mol Imaging (2011) 38:1854–1861 1855in a group of patients who underwent
18F-dopa PETas well
as a careful collection of relevant biochemical tumour
markers whether the total
18F-dopa tumour uptake on PET




For this study we selected all consecutive patients with a
carcinoid tumour (n=77) who underwent
18F-dopa PET as
well as a careful collection of relevant biochemical tumour
markers in two previously published
18F-dopa PET studies
of our institute (between October 2003 and February 2007)
(patients with other neuroendocrine tumours from the
aforementioned studies were not considered for this
analysis) [9, 10]. The inclusion criteria for these studies
were patients with a strong suspicion of a carcinoid tumour,
based on clinical and biochemical findings, and patients
with histopathologically proven carcinoid tumour, with a
clinical indication for (re)staging. All patients had to have
at least one abnormal lesion on conventional imaging.




tryptophan PET in patients with carcinoid tumours. Ex-
tended biochemical analyses were performed and charts
were checked for the presence of somatostatin analogue
treatment. The studies were approved by the Medical Ethics
Committee, and all patients gave informed consent.
18F-dopa PET
18F-dopa was locally produced and performed as described
earlier [9, 10, 19]. In short, whole-body 2-D PET images
were acquired 60 min after the intravenous administration
of
18F-dopa (180±50 MBq). The patients fasted for 6 h
before the examination and were allowed to continue all
medication. For the reduction of tracer decarboxylation
and subsequent renal clearance and to increase tracer
uptake in tumour cells all patients received 2 mg/kg





18F-dopa PETscans were reviewed. For each patient,
a WBMTB was determined as the sum of the metabolic
burden (MB) of each tumour lesion in the PETimage [18].
In order to make the MB independent of body weight and
injected dose the SUV was used, which is defined as:
SUV=activity concentration (MBq/ml)/injected dose per
gram (MBq/g).
In turn, the MB was calculated as: MB=SUVmean ×
volume of tumour lesion. Using this calculation, WBMTB
is expressed as one value (no max or mean as for example
SUV itself). Both SUVmean and tumour volume were
obtained from the PET image using a VOI that was defined
as the tumour volume enclosed by a 40% isodensity surface
[23, 24]. This VOI was semiautomatically drawn. First, the
tumour was fully enclosed by a hand-drawn ellipsoid. In
this preselected volume the SUVmax was established.
Finally, the VOI contained all voxels with values over
40% of the maximum.
Fig. 2 a Illustration of the large difference in metabolic activity
between different lesions within individual patients. On the y-axis for
each individual patient the difference between the highest and lowest
SUV is plotted, each dot representing one patient. This is performed
for both SUVmax and SUVmean, respectively. Horizontal bars represent
the median values. b Distribution of whole-body metabolic burden for
all individual patients (n=76), each dot representing one patient
Table 2 Lesion characteristics
Number of
18F-dopa PET-positive lesions 979
Median number per patient (range) 12 (0–85)
SUVmax, median (range) 3.9 (0.8–33.4)
SUVmean, median (range) 2.6 (0.5–22.7)
V olume in cm
3, median (range) 7.6 (0.55–2,308)
WBMTB in cm
3, range 712 (0–19,000)
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Tumour markers measured for serotonin metabolism were
serotonin concentration in a 24-h urine collection, urinary
and plasma 5-HIAA concentrations [25]. As markers for
catecholamine metabolism we determined urinary and
plasma concentrations of adrenalin, noradrenalin and
dopamine, and urinary concentrations of the major cate-
cholamine metabolites homovanillic acid (HV A), 3,4-dihy-
droxyphenylacetic acid (DOPAC), vanillylmandelic acid
(VMA), vanillic acid (V A), 3-methoxy-4-hydroxyphenyle-
thylglycol (MHPG) metanephrine, normetanephrine and 3-
methoxytyramine (3-MT) in a 24-h urine collection [26,
27]. Serum chromogranin A was determined using a
radioimmunoassay (Cga-React, CIS Bio International, Gif-
sur-Y vette Cedex, France, bioassays@cisbio.com) as a
marker for general neuroendocrine tumour activity (refer-
ence interval 20–100 μg/l) [28].
All laboratory analyses were performed within 3 months
of the
18F-dopa PETscan in the original studies [9, 10].
Statistical analysis
For correlations between WBMTB and biochemical data,
Spearman’s r test was calculated. The significance level
was 0.05, two-sided. The statistical tests were carried out
using the SPSS package version 14.0.
Results
The characteristics of the patients included are shown in
Table 1. Seventy-four patients had metastatic disease. In
76 of 77 carcinoid patients the tumour volume with
18F-
dopa PET generated by the computer using the SUVmean
correlated well with the visual tumour volume (Fig. 1). In
one patient visual inspection of the computer-generated
tumour volume showed a gross underestimation of the
visually identified tumour volume due to enormously
heterogeneous uptake in the metastases. This patient had
an extremely large tumour load in the liver and upper
abdomen, consisting of confluent lesions with varying
uptake intensities in different parts of the tumour. As a
result, the less avid lesions, which had uptake values
below the 40% threshold of the SUVmax of the hottest
lesion, were not included in the lesion volume by the
computer algorithm. Therefore, this patient was excluded
from further analysis.
A total of 979 lesions were detected by
18F-dopa PET
(Table 2).
18F-dopa PET tumour uptake was shown to vary
greatly between carcinoid lesions within individual patients.
Within patients SUVs of different lesions showed a large
variance; this range was wider for SUVmax than for
SUVmean, as the former is more sensitive to outliers. The
median difference between the SUVmax of different lesions
within one patient was 11.6 (range 0.1–28.7) and the
SUVmean 7.2 (0.2–19.7), reflecting the large difference in
metabolic activity between different lesions (Fig. 2a). This
resulted in up to 29-fold differences for SUVmax and 25-
fold for SUVmean within individual patients. This wide
range was caused by difference in size and probable
difference in metabolic activity of the lesions. In addition,
there was a wide range of measured SUVs between
different patients; this range was also wider for SUVmax
(0.8–33.4) than for SUVmean (0.5–22.7). The large vari-
ability was also reflected in widely differing WBMTB
between patients (Fig. 2b). The latter was caused by
varying numbers of lesions between patients as well as by
varying uptake intensities.
Urinary serotonin and/or 5-HIAA levels were elevated in
64 patients (84%). WBMTB showed significant correlations
with both urinary serotonin and its metabolite 5-HIAA in
urine and plasma (Table 3,F i g .3). The strongest correlation
was found between WBMTB and 24-h urinary 5-HIAA.
There was no difference in strength of correlations between
newly diagnosed patients and patients during follow-up.
Elevated levels of catecholamines and/or their metab-
olites were found in 35 patients (46%). The single most
frequently elevated marker was 3-MT, which was
elevated in 17 patients (22%). We found significant
correlations between WBMTB and the urinary levels of
the three main catecholamines norepinephrine, epineph-
rine and dopamine (Table 2). There was no difference
between newly diagnosed patients and patients with
known carcinoid tumour.
Chromogranin A was available for 64 patients; it was
elevated in 35 patients and normal in 29. In the patients
for which chromogranin A was available the serum
levels of chromogranin A did not correlate with WBMTB
(p=0.14) (Fig. 4).
Table 3 Significant correlations between biochemical markers and
18F-dopa PET in total group
Correlation coefficient V ariance explained
by correlation
Urinary serotonin 0.51 0.26
Urinary 5-HIAA 0.78 0.61
Plasma 5-HIAA 0.66 0.44
Urinary norepinephrine 0.53 0.28
Urinary epinephrine 0.38 0.14
Urinary dopamine 0.41 0.17
Urinary 3-MT 0.44 0.19
Plasma dopamine 0.39 0.15
Eur J Nucl Med Mol Imaging (2011) 38:1854–1861 18571858 Eur J Nucl Med Mol Imaging (2011) 38:1854–1861Urinary 5-HIAA and serotonin levels were signifi-
cantly correlated with levels of the three major catechol-
amines norepinephrine, epinephrine and dopamine in 24-
h urine, but not with serum chromogranin A levels (data
not shown).
Discussion
We demonstrated that WBMTB, as measured with
18F-dopa
tumour uptake on PET, correlates with biochemical tumour
markers in patients with a carcinoid tumour, thus reflecting
metabolic endocrine tumour activity. Tracer uptake corre-
lated with urinary and plasma markers of both the serotonin
and the catecholamine pathway, and presented a whole-
body image of the specific sites where endocrine produc-
tion is occurring.
18F-dopa PET tumour uptake was shown
to vary greatly between carcinoid lesions within individual
patients; up to 29-fold differences between individual
lesions were observed. In addition, there was also great
inter-patient variance.
The strongest correlation was found between WBMTB
and urinary 5-HIAA levels. This is interesting considering
the fact that urinary 5-HIAA is the most widely used
marker for follow-up and response assessment of carcinoid
tumours.
Currently, there is some debate about the optimal tumour
marker for follow-up and management of patients with a
carcinoid tumour. Serum chromogranin A has been sug-
gested to replace urinary 5-HIAA [5, 6]. Chromogranin A
plays an important role in the regulation of storage and
secretion of hormones and peptides. It is localised in the
secretory granules of most neuroendocrine cells [29].
Chromogranin Awas shown to correlate with tumour load
in patients with carcinoid tumours [30, 31]. In this study we
clearly show that chromogranin A does not reflect the
metabolic activity of these tumours, since the whole-body
metabolic tumour activity on
18F-dopa PET did correlate
with carefully collected urinary 5-HIAA but not with serum
chromogranin A. As WBMTB is the product of tumour
volume × metabolic tumour activity, and chromogranin A is
known to correlate with tumour burden, it follows that it
does not correlate with metabolic tumour activity. This is
underlined by the fact that in the current study serum
chromogranin A does not correlate with urinary 5-HIAA
levels. 5-HIAA levels are however accepted as markers for
the metabolic activity of the tumour. Little is known about
the correlation between metabolic tumour activity and
serum chromogranin A levels. Although chromogranin A
has been correlated to overall quality of life, it seems not to
reflect the clinically relevant metabolic activity of carcinoid
tumours [6, 8]. An automatically generated WBMTB may
prove to be an interesting marker, since it has demonstrated
a good correlation with the metabolic activity of the
carcinoid tumour.
Currently, the clinical trials with novel promising
targeting agents in these patients to determine progression
are based on RECIST criteria [32], which include only
anatomical tumour size measurements. 5-HIAAs are a
relevant reflection of tumour burden. Regretfully this does
not tell about the biochemical activity of individual lesions
or provide information on for example clinically relevant
well-known mixed responses. This is of major importance
specifically in this disease, which in general is a very
slowly growing tumour, with tumour lesions that are
difficult to interpret with CT and MRI [33, 34]. The fact
that WBMTB measurement provides information about
both size and metabolic activity represents a clear addition-
al advantage. This unique combination might well be used
to guide (invasive) treatment decisions since excellent
tumour localisation and information about the metabolic
tumour activity are both obtained with one scan. Thereby,
lesion activity can be taken into account when contemplat-
ing further treatment. WBMTB on
18F-FDG PET is an
excellent measure of treatment response in non-Hodgkin’s
lymphoma patients [19]. Although not yet investigated in
neuroendocrine tumour patients, WBMTB on
18F-dopa
PET might be an interesting measure of treatment response
in patients with a carcinoid tumour. Prospective studies are
needed to study the usefulness of WBMTB on
18F-dopa
PETas a marker for (early) assessment of response.
In our patients we found a correlation between WBMTB
and catecholamine markers, but these correlations were
weaker than those found between WBMTB and serotonin
markers. This demonstrates that WBMTB correlates not
only with markers of the predominantly active serotonin
pathway, but also with others, such as the catecholamine
Fig. 4 Scatter plot of the correlation between WBMTB and chromog-
ranin A (not significant)
Fig. 3 Scatter plots of the correlation between whole-body metabolic
tumour burden (WBMTB) and a 24-h urinary serotonin, b 24-h urinary
5-hydroxindoleacetic acid (5-HIAA), c plasma 5-HIAA, d 24-h urinary
norepinephrine, e 24-h urinary epinephrine, f 24-h urinary dopamine,
g 24-h urinary 3-methoxytyramine (3-MT)a n dh 24-h plasma
dopamine

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amine concentrations, which conforms with the numbers
found in the literature [1–3]. This is less than the 84% of
patients who had elevated serotonin or 5-HIAA. Intrinsic
tumour catecholamine production explains at least partly
the elevated catecholamine levels in these patients. In about
two thirds of carcinoid tumours at least one of the enzymes
necessary for catecholamine synthesis is present [2]. These
enzymes are focally distributed within the tumour, indicat-
ing that a small subpopulation of carcinoid cells could be
responsible for the catecholamine synthesis in these patients
[2]. Catecholamine levels can also be influenced by
sympathoadrenal activation and medication, which could
provide an alternative explanation for elevated catechol-
amine levels in these patients. These influences affect
catecholamines proportionally much stronger than their
metabolites [35].
Several factors can influence SUVs, thereby influencing
the strength of the correlation between tumour uptake and
biochemical markers. Firstly, the time after injection is an
important variable that can influence SUVs. A previous
study on
18F-dopa PET in carcinoid tumours found that
SUVs did not differ when measured after either 30 or
90 min, indicating that a plateau phase is already reached at
30 min [36]. This was confirmed in other
18F-dopa PET
studies, which showed that most tumour uptake occurred in
the first 30 min and that uptake then remained constant for
at least 100 min [37, 38]. Thus, SUVs measured after
60 min, as was done in our study, render adequate and
reliable measures of tumour tracer uptake. A second factor
is the amount of available tracer. Pretreatment with
carbidopa, a peripheral inhibitor of AADC, is known to
improve image quality for
18F-dopa PET due to higher
tumour to background ratios. Carbidopa further improves
lesion detection through increased SUV values of lesions
[21–23, 37]. The fact that
18F-dopa uptake is visible in
other structures in our scans serves as a visual control for
sufficient tracer availability; otherwise most
18F-dopa
would go to the tumour, as this is the most active tissue.
Primary carcinoid tumours that arise in different parts of
the body show a different likelihood of serotonin and 5-
HIAA production and excretion. The cells of foregut and
hindgut carcinoids express low decarboxylase and therefore
there is a low serotonin and 5-HIAA urinary excretion
when carcinoid tumours originate from these locations [22].
In our study, the majority of patients had a ‘midgut’
carcinoid tumour (82%). However, it cannot be excluded
that the inclusion of patients with foregut and hindgut
tumours could have influenced the strength of the correla-
tions that we found in the current study.
In conclusion, total tumour load per patient defined as
WBMTB measured with
18F-dopa PET correlates with
biochemical markers, reflecting metabolic tumour activity
in carcinoid patients. WBMTB did not correlate with serum
chromogranin A levels, nor did the latter marker correlate
with 5-HIAA levels. WBMTB provides both a measure of
the metabolic tumour activity and a whole-body overview
of the specific sites where endocrine production is occur-
ring, which might be used to guide (invasive) treatment
decisions. In future, WBMTB could serve as an alternative
assessment parameter to evaluate disease extent and
biochemical activity in carcinoid patients. Future studies
should investigate the use of this new parameter for follow-
up or for the assessment of treatment response.
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